Status:
WITHDRAWN
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Lead Sponsor:
AstraZeneca
Conditions:
Bleeding
Eligibility:
All Genders
18-100 years
Brief Summary
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding. Randomization will be performed stratified by geographic ...
Detailed Description
The Group 1 in this trial will consist of a multifaceted bundle of instructions to sites about optimal management of bleeding, including transfusion thresholds and when indicated; laboratory assessmen...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Age ≥ 18 years;
- Patients using chronic OAC (that is, for 30 or more consecutive days) due to AF/flutter, VTE or other clinical indication and presenting with a major bleeding episode according to the definition of the International Society of Thrombosis and Hemostasis (ISTH). Exclusion criteria
- Patients with limitation to follow-up;
- Patients with do not resuscitate order at time of enrolment.
Exclusion
Key Trial Info
Start Date :
January 13 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06575517
Start Date
January 13 2025
End Date
January 13 2025
Last Update
November 24 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.